<DOC>
	<DOCNO>NCT00052520</DOCNO>
	<brief_summary>This phase I/II trial study side effect biological therapy see well work treat patient advanced myelodysplastic syndrome , chronic myeloid leukemia , acute myeloid leukemia , acute lymphoblastic leukemia . Biological therapy , include immunotherapy , potentially used stimulate immune system stop cancer cell grow . Immunotherapy give patient undergone donor stem cell transplantation may way eradicate remain cancer cell</brief_summary>
	<brief_title>Biological Therapy Treating Patients With Advanced Myelodysplastic Syndrome , Acute Chronic Myeloid Leukemia , Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine safety potential toxicity associate infuse donor CD8+ cytotoxic T lymphocyte ( CTL ) clone specific Wilms ' tumor ( WT1 ) patient relapse high risk relapse post transplant myelodysplastic syndrome ( MDS ) , chronic myelogenous leukemia ( CML ) , acute myeloid leukemia ( AML ) , acute lymphoblastic leukemia ( ALL ) . SECONDARY OBJECTIVES : I . To determine vivo persistence transfer T cell assess migration bone marrow , predominant site leukemic relapse . II . To determine adoptively transfer WT1-specific T cell mediate antileukemic activity . OUTLINE : Donors undergo leukapheresis stem cell harvest generate CD8-positive WT1 gene-specific CTL clone time allogeneic stem cell transplantation . After post-transplantation hematopoietic recovery , patient receive treatment either highest-risk disease ( prophylactically ) relapse disease . Highest-risk disease group : Patients receive CD8-positive WT1 gene-specific CTL clone intravenously ( IV ) 1-2 hour day 0 , 14 , 28 . Beginning 2-4 hour CTL infusion , patient receive interleukin-2 subcutaneously ( SC ) twice daily day 28-42 absence unacceptable toxicity . Relapsed-disease group : Some patient evidence leukemic relapse may receive standard salvage chemotherapy prior donor CTL infusion receive CD8-positive WT1 gene-specific CTL clone interleukin-2 highest-risk group . Patients group progressive disease complete partial response therapy may eligible retreatment CD8-positive WT1 gene-specific CTL clone . After completion study treatment , patient follow every 3 month 2 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Anemia , Refractory</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<mesh_term>Anemia , Refractory , Excess Blasts</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Eligibility Enrollment : a. ) Pretransplant : Patients undergo allogeneic hematopoietic stem cell transplantation refractory anemia excess blast ( RAEB ) , refractory anemia excess blast transformation ( RAEBt ) , CML beyond chronic phase , AML beyond first remission , Philadelphia chromosome ( BCRABL ) positive ALL stage , ALL beyond first remission , primary refractory AML ALL , therapyrelated AML stage , acute leukemia stage arise patient antecedent diagnosis myelodysplastic myeloproliferative syndrome ( include chronic myelomonocytic leukemia , CML , polycythemia vera , essential thrombocytosis , agnogenic myeloid metaplasia myelofibrosis ) ; ii ) Posttransplant : Patients relapse transplant ( morphologic , flow cytometric , cytogenetic molecular relapse ) offer enrollment protocol may undergo therapy consider possible control disease wait generation study therapy b . Patients donor must express human leukocyte antigen ( HLA ) allele possible generate WT1specific clone c. Patients must able provide blood bone marrow sample require protocol Eligibility Prophylactic Treatment CD8+ CTL After Transplant ( Highest Risk Subgroup ) : At time plan treatment , CD8+ CTL specific WT1 must generate complete Quality Control ( QC ) test . Patients must &gt; 5 % morphologic blast detectable bone marrow peripheral blood prior time transplant b . Patients must evidence post transplant recovery normal hematopoiesis ( absolute neutrophil count [ ANC ] &gt; 500/mm^3 ) least 7 day prior initiation CTL infusion c. Patients immunosuppressive therapy graftversushost disease ( GVHD ) eligible treatment receive corticosteroid dose corticosteroid taper = &lt; equivalent 0.5 mg/kg/day prednisone ; patient 's symptom remain stable unlikely increase stage III IV acute GVHD chronic GVHD unlikely progress follow change immunosuppressive therapy , appropriate monitoring period , deem patient treat physician principal investigator Eligibility Treatment CD8+ CTL Time Relapse Transplant ( All Others ) : At time plan treatment , CD8+ CTL specific WT1 must generate complete Quality Control ( QC ) test . Patients must evidence recurrent disease post transplant ; include patient follow : ) Morphologic relapse define one following : Abnormal peripheral blast absence growth factor therapy ; abnormal bone marrow blast &gt; 5 % nucleated cell ; extramedullary chloroma granulocytic sarcoma ii ) Flow cytometric relapse define : appearance peripheral blood bone marrow cell abnormal ; immunophenotype detect flow cytometry consistent leukemia recurrence iii ) Cytogenetic relapse define : appearance one metaphases bone marrow peripheral blood cell either nonconstitutional cytogenetic abnormality identify least one cytogenetic study perform prior transplant new abnormality know associated leukemia ; ( CML ) increase number Ph+ metaphases bone marrow peripheral blood two consecutive sample engraftment , ; increase percentage BCR/ABL+ cell fluorescence situ hybridization ( FISH ) two consecutive sample engraftment iv ) Molecular relapse define : one positive polymerase chain reaction ( PCR ) assay presence clonotypic immunoglobulin heavy chain ( IgH ) T cell receptor ( TCR ) gene rearrangement patient transplant Bor Tcell acute lymphoblastic leukemia , respectively ; one positive post transplant reverse transcription ( RT ) PCR assay presence BCRABL messenger ribonucleic acid ( mRNA ) fusion transcript patient transplant Philadelphia chromosome ( BCRABL ) positive acute lymphoblastic leukemia ; ( CML ) PCR assay bone marrow ( BM ) peripheral blood mononuclear cell ( PBMC ) positive presence BCR/ABL mRNA fusion transcript quantitatively increase great one order magnitude subsequent sample b . Patients immunosuppressive therapy GVHD time relapse eligible treatment receive corticosteroid dose corticosteroid taper &lt; equivalent 0.5 mg/kg/day prednisone ; patient 's symptom remain stable unlikely increase stage III IV acute GVHD chronic GVHD unlikely progress follow change immunosuppressive therapy , appropriate monitoring period , deem patient treat physician principal investigator DONOR : Both patient donor must HLAallele possible generate WT1specific clone DONOR : If separate leukapheresis via peripheral intravenous access arrange , stem cell donor undergo leukapheresis provide require PBMC sooner 2 week stem cell mobilization harvest DONOR : If separate leukapheresis possible , portion PBMC donor 's peripheral blood stem cell harvest may potentially used generate WT1specific CTL clone ; feasibility option depend upon minimal cell dose require transplantation presence excess harvest yield possibility generate CTL product DONOR : Some donor ask provide separate leukapheresis portion peripheral blood mononuclear cell ( PBMC ) donor 's peripheral blood stem cell harvest DONOR : Leukapheresis donor must age 18 old Patients CD8+ CTL clone specific WT1 generate time plan infusion ( patient potentially treat later CTL become available ) ; Also exclude patient whose malignant cell express WT1 , base direct analysis bone marrow sample &gt; 50 % blast leukemia cell isolated expression analysis ; either case patient informed availability treatment protocol might eligible Patients Karnofsky performance status Lansky play score = &lt; 30 % Patients current stage III IV GVHD unresponsive therapy require therapy antiCD3 mAb , prednisone &gt; 0.5 mg/kg/day ( corticosteroid equivalent ) , treatment result ablation inactivation T cell ( antiT cell monoclonal antibody ) ; although concurrent use cyclosporine , FK506 , MMF strictly exclusion criterion , attempt make discontinue possible Patients require concurrent therapy hydroxyurea agent may interfere function survival infuse CTL clone Patients preexist nonhematopoietic organ toxicity deem principal investigator place patient unacceptable risk treatment protocol Patients graft rejection failure DONOR : Medical condition preclude either leukapheresis blood donation may include limited : Inadequate age weight ( leukapheresis donor must age 18 old , criterion per physician discretion ) Active infection , without antibiotic treatment Recent hepatitis exposure , hepatitis A B antigenemia , hepatitis C antibody positivity Pregnancy nursing ; HIV human Tlymphotropic virus ( HTLV ) infection Severe cardiovascular disease ( e.g. , uncontrolled hypertension , recent myocardial infarction [ MI ] , unstable angina )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>